The Worldwide Market for Liquid Biopsy, 6th Edition
상품코드:1399822
리서치사:Kalorama Information
발행일:2023년 12월
페이지 정보:영문 220 Pages
라이선스 & 가격 (부가세 별도)
한글목차
액체 생검은 체액을 순환하는 종양 유래 물질을 분석하여 암의 진단, 치료 및 모니터링을 위한 귀중한 정보를 제공하는 최소 침습적 진단 도구로 등장했습니다. 조직 생검과 영상 진단 기술이 여전히 고형암 진단의 표준이지만, 액체 생검은 기존 방법의 한계와 위험성을 극복할 수 있는 대체 또는 보완적인 접근법입니다.
본 보고서는 세계의 액체 생검(Liquid Biopsy) 시장에 대해 조사했으며, 시장 개요와 함께 분석 대상별/용도별/암종별/지역별 동향, 시장 진출기업 프로파일 등을 정리하여 전해드립니다.
목차
제1장 주요 요약
제2장 액체생검 기술
서론
현재의 주요 액체생검 기술
제3장 순환 종양 DNA(ctDNA) 액체생검
제4장 순환종양세포(CTC) 액체생검
제5장 세포외소포 및 기타 액체생검
제6장 복수 검체 액체생검 검사
제7장 연구 목적의 액체생검 검사
제8장 액체생검 업계 분석
서론
경쟁 단계
경쟁 요인
중요 시장 동향
맞춤형 의료
세계 평균수명 연장
새로운 액체생검 제품
유전자 검사의 접근성 향상
규제 장벽
제3자 지불자의 보상 범위
증명된 임상적 유용성
특정 암의 발생률
경쟁사는 액체생검 시장에서 철퇴
제9장 액체생검 시장
시장 개요
시장 예측
제10장 분석 대상물별 시장
순환종양 DNA
순환종양 세포
세포외소포 및 기타
제11장 용도별 시장
치료 가이던스 및 모니터링
진단 및 스크리닝
질병의 예후
제12장 암 유형별 시장
유방암
대장암
폐암
난소암
전립선암
기타
제13장 기업 개요
시장 기업
Adaptive Biotechnologies
Agena Bioscience, Inc
ANGLE, plc
Aspira Women's Health
Biocartis Group NV
Biocept, Inc.
Biodesix
CellMax Life
Circulogene
DiaCarta, Inc
Epic Sciences
Epigenomics AG
Exact Sciences
Exosome Diagnostics, Inc.
Foundation Medicine, Inc.
Freenome, Inc
GILUPI GmbH
GRAIL
Guardant Health, Inc
Hologic
LungLife AI
Menarini-Silicon Biosystems, Spa
Myriad Genetics, Inc
Natera, Inc
NeoGenomics Laboratories, Inc
Oncocyte Corporation
OncoDNA S.A.
Personal Genome Diagnostics
QIAGEN N.V.
Resolution Biosciences
Roche Diagnostics
Sysmex-Inostics, Inc
Tempus
VolitionRx
LSH
영문 목차
영문목차
Liquid biopsies have emerged as a minimally invasive diagnostic tool, analyzing tumor-derived materials circulating in biological fluids to offer valuable information for cancer diagnosis, treatment, and monitoring. While tissue biopsies and imaging techniques remain standard in solid tumor diagnosis, liquid biopsies present an alternative or complementary approach, addressing some of the limitations and risks associated with traditional methods.
Key applications of liquid biopsy testing in clinical oncology include:
1. Early Detection and Diagnosis/Screening:
Identifying cancer at an early stage.
2. Alternative Testing Method:
When tissue biopsy is challenging or impossible.
When the primary site of metastatic disease is unknown.
3. Therapy Personalization and Monitoring:
Molecular characterization to select optimal therapy.
Monitoring treatment efficacy and adjusting therapy in case of resistance.
Assessing the likely course and outcome of the disease.
The liquid biopsy market is experiencing significant changes, and “ The Worldwide Market for Liquid Biopsy, 6th Edition ” from Kalorama Information provides an in-depth assessment of the market opportunity from 2023 to 2028. The brand new market research report covers various aspects, including market segmentation by region, different types of liquid biopsy (CTC-based, ctDNA-based, EV and Exosome-based, Multi-Analyte-based, and Other Analytes), and cancer types.
Key Market Segments:
By Region:
North America
Europe
Asia
Rest of World
By Type of Liquid Biopsy:
CTC-based Liquid Biopsy
ctDNA-based Liquid Biopsy
EV and Exosome-based Liquid Biopsy
Multi-Analyte-based Liquid Biopsy
Other Analytes Liquid Biopsy
By Type of Cancer:
Breast
Lung
Colorectal
Ovarian
Prostate
Pan-Cancer
Other Cancers
R&D and Selected Tests:
Selected ctDNA-based Liquid Biopsy Tests in Development
Selected CTC-based Liquid Biopsy Tests in 2023
Selected Liquid Biopsy Tests Assessing Multiple Analytes in 2023
The growing acceptance of liquid biopsy, even during the 6th pandemic, underscores its increasing significance in clinical diagnostics. Liquid biopsy's potential in combination with other technologies further contributes to its expanding applications and market growth.
The report also profiles key companies in the liquid biopsy market. These include:
Top of Form
Bottom of Form
Adaptive Biotechnologies
Agena Bioscience, Inc.
Angle, PLC
Aspira Women's Health
Biocartis Group Nv
Biocept, Inc. (closed)
Biodesix
Cellmax Life
Circulogene
Diacarta, Inc.
Epic Sciences
Epigenomics AG (closed)
Exact Sciences
Exosome Diagnostics, Inc.
Foundation Medicine, Inc. (Roche)
Freenome, Inc.
Gilupi Gmbh
Grail (Illumina)
Guardant Health, Inc.
Hologic
Lunglife AI (Formerly Cynvenio Biosystems)
Menarini-Silicon Biosystems, SPA
Myriad Genetics, Inc.
Natera, Inc.
Neogenomics Laboratories, Inc.
Oncocyte Corporation
Oncodna S.A.
Personal Genome Diagnostics
Qiagen N.V.
Cell-Free DNA Technologies
Ctc Technologies
Exosome And Mirna Technologies
Resolution Biosciences (Agilent)
Roche Diagnostics
Sysmex-Inostics, Inc.
Tempus
Volitionrx
Table of Contents
Chapter One: Executive Summary
Introduction
Liquid Biopsy Technologies
Industry Structure
Liquid Biopsy Market Revenues and Forecast
Figure 1-1: Market for Liquid Biopsy, 2023-2028 ($M)
Figure 1-2: Global Liquid Biopsy Market Share, by Geographic Region, 2023 (%)
Table 1-1: Global Liquid Biopsy Market by Geographic Region, 2023-2028 ($M)
Chapter Two: Liquid Biopsy Technologies
Introduction
Table 2-1: Comparison of Tissue and Liquid Biopsy
Current Major Liquid Biopsy Technologies
Table 2-2: Advantages and Limitations of Major Liquid Biopsy Technologies
Chapter Three: Circulating Tumor DNA (ctDNA) Liquid Biopsy
Introduction
Advantages and Limitations of ctDNA in Liquid Biopsy
